<SEC-DOCUMENT>0001140361-21-030388.txt : 20210903
<SEC-HEADER>0001140361-21-030388.hdr.sgml : 20210903
<ACCEPTANCE-DATETIME>20210903170101
ACCESSION NUMBER:		0001140361-21-030388
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20210903
DATE AS OF CHANGE:		20210903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-256643
		FILM NUMBER:		211237248

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ny20000594x1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge Financial Solutions, Inc.
         Document created using EDGARfilings PROfile 7.5.1.0
         Copyright 1995 - 2021 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;" bgcolor="#ffffff">
  <div>
    <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  <div>
    <div style="text-align: right; font-weight: bold;">Filed Pursuant to Rule 424(b)(5)</div>
    <div style="text-align: right; font-weight: bold;">Registration No. 333-256643</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Prospectus Supplement</div>
    <div style="font-weight: bold;">(To prospectus dated May 28, 2021)</div>
    <div><br>
    </div>
    <div style="text-align: center;"><img src="ny20000594x1_424b5-image01.jpg"> </div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;">Up to $50,000,000</div>
    <div style="text-align: center; font-style: italic;">Common Stock</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: normal; font-weight: normal;">We have entered into a Distribution Agreement (the &#8220;Distribution Agreement&#8221;) with Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;), dated September 3, 2021, relating to
      the sale of shares of our common stock, par value $0.0001 per share (the &#8220;common stock&#8221;), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Distribution Agreement, we may offer and sell shares
      of our common stock, having an aggregate offering price of up to $50,000,000 from time to time through Raymond James, acting as agent.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be &#8220;at the market offerings&#8221; as defined in Rule 415(a)(4) promulgated under the
      Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), including sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. Raymond James is not required to sell any specific amount, but
      will act as our sales agent using commercially reasonable efforts, consistent with its normal trading and sales practices. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Raymond James will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price per share sold under the Distribution Agreement. See &#8220;Plan of Distribution&#8221; beginning on page S-14 for
      additional information regarding the compensation to be paid to Raymond James. In connection with the sale of the common stock on our behalf, Raymond James will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the
      compensation of Raymond James will be deemed to be underwriting commissions or discounts. We also have agreed to provide indemnification and contribution to Raymond James with respect to certain liabilities, including liabilities under the Securities
      Act.</div>
    <div style="font-weight: normal;"><br>
    </div>
    <div style="text-align: justify; font-style: normal; font-weight: normal;">Our common stock is listed on the Nasdaq Global Market under the trading symbol &#8220;ADMA.&#8221; On September 1, 2021, the last reported sale price of our common stock on the Nasdaq
      Global Market was $1.33 per share.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">Investing in our common stock involves risks. See &#8220;Risk Factors&#8221; beginning on page S-9 of this prospectus.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this
      prospectus. Any representation to the contrary is a criminal offense.</div>
    <div><br>
    </div>
    <div style="font-size: 18pt; text-align: center; font-weight: bold;">Raymond James</div>
    <div>
      <div><br>
      </div>
      <div style="text-align: center;">The date of this prospectus is September 3, 2021.</div>
      <div><br>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;">TABLE OF CONTENTS</div>
    <div><br>
    </div>
    <div style="font-weight: bold;">Prospectus Supplement</div>
    <div><br>
    </div>
    <a name="ABOUTTHISPROSPECTUSSUPPLE"><!--Anchor--></a>
    <table id="zbafa77d5ded84b5e8c76cde74d8cbc2e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td rowspan="1" style="background-color: #FFFFFF; vertical-align: top; width: 96%;">&#160;</td>
          <td rowspan="1" style="background-color: rgb(255, 255, 255); vertical-align: top; width: 4%; text-align: center;">&#160;<font style="font-weight: bold;">Page</font></td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#ABOUTTHISPROSPECTUSSUPP">ABOUT THIS PROSPECTUS SUPPLEMENT</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#ABOUTTHISPROSPECTUSSUPP">S-1</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#CAUTIONARYNOTICEREGARDING">CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#CAUTIONARYNOTICEREGARDING">S-3</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#PROSPECTUSSUPPLEMENTSUMMA">PROSPECTUS SUPPLEMENT SUMMARY</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#PROSPECTUSSUPPLEMENTSUMMA">S-5</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#THEOFFERING">THE OFFERING</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#THEOFFERING">S-8</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#RISKFACTORS">RISK FACTORS</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#RISKFACTORS">S-9</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#USEOFPROCEEDS">USE OF PROCEEDS</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#USEOFPROCEEDS">S-11</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#DIVIDENDPOLICY">DIVIDEND POLICY</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#DIVIDENDPOLICY">S-12</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#DILUTION">DILUTION</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#DILUTION">S-13</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#PLANOFDISTRIBUTION">S-14</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#LEGALMATTERS">LEGAL MATTERS</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#LEGALMATTERS">S-16</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#EXPERTS">EXPERTS</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#EXPERTS">S-16</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#WHEREYOUCANFINDMOREINFORM">WHERE YOU CAN FIND MORE INFORMATION</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#WHEREYOUCANFINDMOREINFORM">S-16</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#INCORPORATIONOFCERTAINDOC">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#INCORPORATIONOFCERTAINDOC">S-16</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-weight: bold;">Prospectus</div>
    <div><br>
    </div>
    <table id="z4496db786384469981e3e3de3a78b749" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="width: 96%; vertical-align: top;">&#160;</td>
          <td style="width: 4%; vertical-align: top;">
            <div style="font-weight: bold; text-align: center;">Page</div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#ABOUTTHISPROSPECTUS">About This Prospectus</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#ABOUTTHISPROSPECTUS">2</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#THECOMPANY">The Company</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#THECOMPANY">3</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#RISKFACTORS-2">Risk Factors</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#RISKFACTORS-2">5</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#SPECIALNOTEREGARDINGFORWA">Special Note Regarding Forward-Looking Statements</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#SPECIALNOTEREGARDINGFORWA">6</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#USEOFPROCEEDS-2">Use of Proceeds</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#USEOFPROCEEDS-2">8</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#DESCRIPTIONOFTHESECURITIE">Description of the Securities We May Offer</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#DESCRIPTIONOFTHESECURITIE">9</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#DESCRIPTIONOFCAPITALSTOCK">Description of Capital Stock</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#DESCRIPTIONOFCAPITALSTOCK">9</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#DESCRIPTIONOFDEBTSECURITI">Description of Debt Securities</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#DESCRIPTIONOFDEBTSECURITI">12</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#DESCRIPTIONOFWARRANTS">Description of Warrants</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#DESCRIPTIONOFWARRANTS">12</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#DESCRIPTIONOFUNITS">Description of Units</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#DESCRIPTIONOFUNITS">12</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#LEGALOWNERSHIPOFSECURITIE">Legal Ownership of Securities</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#LEGALOWNERSHIPOFSECURITIE">12</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#PLANOFDISTRIBUTION-2">Plan of Distribution</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#PLANOFDISTRIBUTION-2">16</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#WHEREYOUCANFINDMOREINFORM-2">Where You Can Find More Information</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#WHEREYOUCANFINDMOREINFORM-2">19</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#INCORPORATIONOFCERTAINDOC-2">Incorporation of Certain Documents by Reference</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#INCORPORATIONOFCERTAINDOC-2">19</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div><a href="#LEGALMATTERS-2">Legal Matters</a></div>
          </td>
          <td style="width: 4%; vertical-align: top; background-color: rgb(204, 238, 255);">
            <div style="text-align: right;"><a href="#LEGALMATTERS-2">20</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 96%; vertical-align: top;">
            <div><a href="#EXPERTS-2">Experts</a></div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="text-align: right;"><a href="#EXPERTS-2">20</a></div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">For further information regarding us and our financial information, you should refer to our recent filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;). See the sections titled &#8220;Where You Can Find More
      Information&#8221; and &#8220;Incorporation of Certain Documents by Reference.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">You should rely only on the information contained or incorporated by reference in this prospectus supplement or the accompanying prospectus. Neither we nor Raymond James have authorized anyone to provide you with
      information different from that contained in or incorporated by reference into this prospectus supplement or the accompanying prospectus. We are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales
      are permitted. The information contained in this prospectus supplement and the accompanying prospectus is accurate only as of the date of this prospectus supplement and the accompanying prospectus, regardless of the time of delivery of this
      prospectus supplement and the accompanying prospectus or of any sale of our common stock.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">No action is being taken in any jurisdiction outside the United States to permit a public offering of the common stock or possession or distribution of this prospectus supplement or the accompanying prospectus in that
      jurisdiction. Persons who come into possession of this prospectus supplement or the accompanying prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the
      distribution of this prospectus supplement or the accompanying prospectus applicable to that jurisdiction.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%S-%%-->
    <div style="text-align: center; font-weight: bold;"><a name="ABOUTTHISPROSPECTUSSUPP"><!--Anchor--></a>ABOUT THIS PROSPECTUS SUPPLEMENT</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This prospectus supplement and the accompanying prospectus are part of a &#8220;shelf&#8221; registration statement on Form S&#8209;3 that we initially filed with the SEC on May 28, 2021 (File No. 333-256643), and that was declared
      effective by the SEC on August 3, 2021. Under the shelf registration process, we may offer shares of our common stock having an aggregate offering price of up to $250,000,000 from time to time at prices and on terms to be determined by market
      conditions at the time of offering.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We provide information to you about this offering of shares of our common stock in two separate documents that are bound together: (1) this prospectus supplement, which describes the specific details regarding this
      offering; and (2) the accompanying base prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If information in this
      prospectus supplement is inconsistent with the accompanying base prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in a document having a later date
      incorporated by reference in this prospectus supplement, the statement in the document incorporated by reference modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed
      since the earlier dates. This prospectus supplement supersedes and replaces the prospectus dated May 28, 2021 in its entirety. You should keep this prospectus supplement for future reference.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in
      connection with this offering. We have not, and Raymond James has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not,
      and Raymond James is not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so
      or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement and the accompanying prospectus, the documents incorporated by reference into this prospectus
      supplement and the accompanying prospectus, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results
      of operations and prospects may have changed since those dates. You should read this prospectus supplement and the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and
      any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in
      the sections of this prospectus entitled &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and
      the offering of the common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement or the accompanying prospectus must inform themselves about, and observe any
      restrictions relating to, the offering of the common stock and the distribution of this prospectus supplement or the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus does not constitute,
      and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such
      person to make such an offer or solicitation.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete
      information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated herein by reference as exhibits to the registration
      statement, and you may obtain copies of those documents as described below under the section titled &#8220;Where You Can Find More Information.&#8221;</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of
      the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties
      or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">This prospectus supplement and the accompanying prospectus contain and incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other
      publicly-available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any
      misstatements regarding the market and industry data presented in this prospectus supplement, the accompanying prospectus or the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change
      based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; in this prospectus supplement and the accompanying prospectus, and under similar headings in the other documents that are incorporated herein by reference.
      Accordingly, investors should not place undue reliance on this information.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">ADMA&#8217;s name and logo are either registered trademarks or trademarks of ADMA Biologics, Inc. in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this
      prospectus supplement and the accompanying prospectus are the property of their respective owners. Unless otherwise mentioned or unless the context requires otherwise, all references in this prospectus supplement and the accompanying prospectus to
      the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or similar references mean ADMA Biologics, Inc., a Delaware corporation, and its wholly owned subsidiaries, ADMA BioCenters Georgia, Inc., a Delaware corporation (&#8220;ADMA BioCenters&#8221;), ADMA BioManufacturing,
      LLC, a Delaware limited liability company (&#8220;ADMA BioManufacturing&#8221;), and ADMA Plasma Biologics, Inc., a Delaware corporation (&#8220;ADMA Plasma Biologics&#8221;).</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This prospectus supplement and the accompanying prospectus include our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>,&#8221;
      &#8220;Nabi-HB&#174;&#8221; and &#8220;BIVIGAM&#174;,&#8221; which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this
      prospectus supplement may appear without the &#174;, <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> or <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> symbols, but such references
      are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display
      of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="CAUTIONARYNOTICEREGARDING"><!--Anchor--></a>CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of Section
      27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and such forward-looking statements involve risks and uncertainties. These forward-looking statements include, but are not limited to,
      statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221;
      &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; or the negative thereof, or other variations or comparable terminology, although some forward-looking statements are expressed differently. The forward-looking statements included herein
      represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. These statements include statements about:</div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd98c40506f404d20a5c9420ffe45c9e2" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our ability to continue as a going concern;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd2cf5ab15c9f41c88954ac94d595a211" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our intended use of the proceeds derived from this offering;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z9e2b1c9985c04f3085697f3f2d02a27e" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top;">
                  <div style="text-align: justify;">our ability to manufacture BIVIGAM and ASCENIV on a commercial scale and commercialize these products as a result of their approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in 2019;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb13a392c6bcd4dc1812ae9b9e0a6e798" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zd0cce6efd7894fd581421683bdf192e1" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the labeling or nature of any such approvals;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zc116abfd3af84e9d9821d0a8601e2403" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb81edc86f99843a481443526b0409355" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our dependence upon our third-party customers and vendors and their compliance with applicable regulatory requirements;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7afc931e990644069561189d552f8c45" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our belief that we have addressed the delays experienced with final drug product Good Manufacturing Practices release testing by our third-party vendors by adding additional release testing laboratories
                    to our FDA-approved consortium listed in our drug approval documents;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z97d137943cab47c0a524965be7904bf1" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z14d6cff9fa1f493790c19a55c001e70d" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our plans to increase our supplies of source plasma, which include plasma collection center expansion and reliance on third-party supply agreements as well as any extensions to such agreements;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z42e649cf5ca549cc97083dde945c0619" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the potential indications for our products and product candidates;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z94d8fe7e95a64eb996d177742ae03cb8" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">potential investigational new product applications;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z00d303370fe943698689cf4ec8977689" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the acceptability of any of our products, including BIVIGAM, ASCENIV and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or payers;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zc8eabc0b2c32494589154c6d27c496fb" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0d2f09ba3d824d11b2da2e58a2364ee6" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <div>
                  <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za0aaa8ab4bc94c4a97b9c49f8e4aa3a4" class="DSPFListTable" cellpadding="0" cellspacing="0">

                      <tr style="vertical-align: top;">
                        <td style="width: 36pt;">&#160;</td>
                        <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                        <td style="vertical-align: top; width: auto;">
                          <div style="text-align: justify;">concurrence by the FDA with our conclusions concerning our products and product candidates;</div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z009bd463771e42a2b863caf5fead4aca" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the comparability of results of our hyperimmune and immune globulin (&#8220;IG&#8221;) products to other comparably run hyperimmune and immune globulin clinical trials;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z1d796492a19143eca89b07ad32c8e397" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with Primary Immune Deficiency Disease, Primary Humoral Immunodeficiency Disease (&#8220;PIDD&#8221; or &#8220;PI&#8221;) or
                    other immune deficiencies or any other condition for which the products may be prescribed or evaluated;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb27574fc60da482a8bf271b5243edf52" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful revenues from this product;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="za896b58dcfa844fcb42031871869df33" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV or other future pipeline product candidates;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zb44906f9338341d98d4b8ee0aa5e63be" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zba0ec2920b324f0098ab944fc5dffc99" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our plans related to the expansion of our manufacturing capacity, yield improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and other collaborative agreements and the
                    success of such endeavors;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z295ce70852bf45d1bad86c4066ca1e26" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our estimates regarding revenues, expenses, capital requirements, timing to profitability and the need for and availability of additional financing;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zdd64e97f2dcb4bb2bfaf5b581f2e7445" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">possible or likely reimbursement levels for our currently marketed products;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z13fbe316fa7c4eaa8500514e6e4c6f53" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z78f74b569ad24f069d74d2354acb2849" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">effects of the coronavirus COVID-19 pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted
                    prior to the macroeconomic effects of the COVID-19 pandemic;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z0d4ef3e4b284440fa4adecdb83ca13dc" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">future domestic and global economic conditions or performance; and</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z89a91470a875489884173425d658e05d" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">expectations for future capital requirements.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">Forward-looking statements involve risks and uncertainties that could cause actual results or outcomes to differ materially from those expressed therein. We express our estimates, expectations, beliefs, and projections
      in good faith and believe them to have a reasonable basis. However, we make no assurances that management&#8217;s estimates, expectations, beliefs, or projections will be achieved or accomplished. Important factors that could cause actual results to differ
      materially from those discussed in our forward-looking statements are discussed in &#8220;Risk Factors,&#8221; beginning on page S-9 of this prospectus; Part I, Item 1A. Risk Factors of our Form 10-K for the year ended December 31, 2020 (the &#8220;2020 10-K&#8221;); Part
      II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of our 2020 10-K; Part II, Item 1A. Risk Factors of our Form 10-Q for the quarter ended June 30, 2021; and other parts of this prospectus supplement.</div>
    <br>
    <div style="text-align: justify;">Any forward-looking statement speaks only as to the date on which that statement is made. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this
      prospectus supplement, except as may otherwise be required by the federal securities laws.</div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; border: 2px solid #000000; padding: 5px; width: 99%;">
      <div>
        <div style="text-align: center; font-weight: bold;"><a name="PROSPECTUSSUPPLEMENTSUMMA"><!--Anchor--></a> PROSPECTUS SUPPLEMENT SUMMARY</div>
        <div><br>
        </div>
        <div style="font-style: italic;">This summary highlights certain information about us, this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement and the accompanying prospectus. This
          summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, we encourage you to read and
          consider carefully the more detailed information in this prospectus supplement and the accompanying prospectus, including the information incorporated by reference in this prospectus supplement and the accompanying prospectus, including the
          information under the section titled &#8220;Risk Factors&#8221; in this prospectus beginning on page S&#8209;9 and in the documents incorporated by reference into this prospectus supplement and the accompanying prospectus.</div>
        <div><br>
        </div>
        <div style="font-weight: bold;">Our Business</div>
        <div><br>
        </div>
        <div>We are an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for
          certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>
        <div><br>
        </div>
        <div>We currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin Intravenous, Human), an Intravenous Immune Globulin
          (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;
          (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; and (iii) Nabi-HB
          (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product
          based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin manufactured to contain standardized antibodies to numerous
          serotypes of S. pneumoniae. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</div>
        <div><br>
        </div>
        <div>We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the &#8220;Boca Facility&#8221;). Based on current
          production yields, our ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce quantities of our immune globulin products of more than $250 million in annual revenue beginning in
          2024 and potentially in excess of $300 million of annual revenue thereafter, as well as achieving profitability during the first quarter of 2024, as we ramp-up production over the next three to five years. We anticipate exiting 2021 approaching
          an annualized revenue run rate of approximately $100 million or more.</div>
        <div><br>
        </div>
        <div>Through our ADMA BioCenters subsidiary, we currently operate FDA-licensed source plasma collection facilities in the U.S. This business unit, which we refer to as our Plasma Collection Centers business segment, provides us with a portion of
          our blood plasma for the manufacture of our products and product candidates, and also allows us to sell certain quantities of source plasma to customers for further manufacturing. As a part of our planned supply chain robustness initiative, we
          currently have eight plasma centers under our corporate umbrella, including three FDA-approved facilities, with five of those facilities now open and collecting plasma and two additional Biologics License Applications filings anticipated over the
          remainder of 2021. We remain on track to have 10 or more FDA-approved plasma collection facilities by 2024.&#160; In addition, one of our FDA-approved plasma collection centers also has approvals from the Korean Ministry of Food and Drug Safety, as
          well as FDA approval to operate a Hepatitis B immunization program. After giving effect to the progress we made in 2020 and thus far in 2021 with our plasma collection network expansion, we believe that we remain on track to achieve our goal of
          having 10 or more plasma collection centers operating in the U.S. by 2024. A typical plasma collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be
          sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products or product candidates is
          sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221; market.</div>
      </div>
      <div><br>
      </div>
    </div>
    <div style="text-align: justify;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-5</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; border: 2px solid #000000; padding: 5px; width: 99%;">
      <div>
        <div style="font-weight: bold;">Our Products</div>
        <div><br>
        </div>
        <div style="font-style: italic; font-weight: bold;">BIVIGAM</div>
        <div><br>
        </div>
        <div>BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses, and help to protect PI patients against serious infections.
          BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not limited to, the humoral immune defect in common
          variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders. Based on recent estimates, these disorders are no
          longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</div>
        <div><br>
        </div>
        <div>On May 9, 2019, the FDA approved the Prior Approval Supplement for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the United States. We resumed production of BIVIGAM during the
          fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial re-launch and first commercial sales for
          this product commenced in August of 2019.</div>
        <div><br>
        </div>
        <div>On April 28, 2021, we announced that the FDA has granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. We expect this increased IVIG
          plasma pool scale, which will allow us to produce BIVIGAM at an expanded capacity, will utilize the same equipment, release testing assays and labor force, and to have a favorable impact on our gross margins and operating results, potentially
          beginning late in the fourth quarter of 2021.</div>
        <div><br>
        </div>
        <div style="font-style: italic; font-weight: bold;">ASCENIV</div>
        <div><br>
        </div>
        <div>ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and prevent against infection and
          disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services has issued a permanent, product-specific-J-code for ASCENIV. Under the Healthcare Common Procedure
          Coding System, the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends
          normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus (&#8220;RSV&#8221;) using our proprietary microneutralization testing assay. We are able to identify the high titer or
          &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV with our patented testing methods and assay. This type of high titer plasma is typically found in less than 10% of the total donor collection samples we test.</div>
        <div><br>
        </div>
        <div>ASCENIV is approved for the treatment of PIDD, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of age). Our pivotal Phase 3 clinical trial in 59 PIDD patients met
          the primary endpoint of no Serious Bacterial Infections reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV in the low incidence of infection, therapeutic antibiotic use, days missed
          from work/school/daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of PIDD better positions ADMA to further evaluate ASCENIV in immune-compromised patients
          infected with or at-risk for RSV infection or potentially other respiratory viral pathogens. Due to the COVID-19 pandemic, our plans have been delayed. In the future, however, we plan to work with the FDA and the immunology and infectious disease
          community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population. Commercial sales of ASCENIV commenced in October of 2019.</div>
        <div><br>
        </div>
        <div style="font-style: italic; font-weight: bold;">Nabi-HB</div>
        <div><br>
        </div>
        <div>Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a Hepatitis B vaccine. Nabi-HB
          is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute Hepatitis B virus
          infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus. It is a major global health problem. It can cause chronic infection and puts people at high risk of death from
          cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.&#160; Production of Nabi-HB at the Boca Facility has continued
          under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the U.S. and we continue to manufacture Nabi-HB
          under HHS License No. 2019.</div>
      </div>
      <div><br>
      </div>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-6</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">
      <div> <br>
      </div>
      <div style="border: 2px solid #000000; padding: 5px; width: 99%;">
        <div>
          <div style="font-weight: bold;">Corporate Information</div>
          <div><br>
          </div>
          <div>ADMA Biologics, Inc. was founded on June 24, 2004 as a New Jersey corporation and re-incorporated in Delaware on July 16, 2007. We operate through our wholly-owned subsidiaries ADMA BioManufacturing, ADMA BioCenters and ADMA Plasma
            Biologics.</div>
          <div><br>
          </div>
          <div>We maintain our headquarters at 465 State Route 17, Ramsey, NJ 07446. Our telephone number is (201) 478-5552. Our Florida campus is located at 5800 Park of Commerce Boulevard, Northwest, Boca Raton, FL 33487. The Florida telephone number is
            (561) 989-5800. We maintain a website at www.admabiologics.com; however, the information on, or that can be accessed through, our website is not part of this prospectus supplement. This prospectus supplement and all of our filings under the
            Exchange Act, including copies of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, are available free of charge through our website on the date we file those
            materials with, or furnish them to, the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Such filings are also available to the public on the SEC&#8217;s website at www.sec.gov.</div>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-7</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
    </div>
    <br>
    <div>
      <div style="text-align: center; font-weight: bold;"><a name="THEOFFERING"><!--Anchor--></a>THE OFFERING</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Common stock offered by us:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Shares of our common stock having an aggregate offering price of up to $50,000,000.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Common stock to be outstanding immediately after the offering:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Up to 37,593,984 shares, assuming the sale of $50,000,000 of shares of our common stock in this offering at a price of $1.33 per share, which was the closing price of our common stock on the Nasdaq Global
                Market on September 1, 2021. The actual number of shares issued will vary depending on the sales price under this offering.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Manner of offering:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">&#8220;At-the-market&#8221; offering that may be made from time to time through our sales agent, Raymond James &amp; Associates, Inc. See &#8220;Plan of Distribution&#8221; beginning on page S-14.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Use of proceeds:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">We intend to use the net proceeds from this offering, if any, for general corporate purposes, including procurement of raw materials, source plasma, supply chain initiatives and production expenditures,
                funding expansion of plasma centers, working capital, capital expenditures, expansion and resources for commercialization activities, and other potential research and development and business opportunities.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Risk factors:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Investing in our common stock involves significant risks. See &#8220;Risk Factors&#8221; beginning on page S-9, and under similar headings in other documents incorporated by reference into this prospectus.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">Nasdaq Global Market symbol:</div>
            </td>
            <td style="width: 50%; vertical-align: top;">
              <div style="text-align: justify;">&#8220;ADMA&#8221;</div>
            </td>
          </tr>

      </table>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">The number of shares of our common stock to be outstanding immediately after this offering is based on 131,872,026 shares of common stock outstanding as of June 30, 2021, and excludes:</div>
      <div>
        <div><br>
        </div>
        <div>
          <div>
            <div>
              <div>
                <div>
                  <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                      <tr style="vertical-align: top;">
                        <td style="width: 36pt;">&#160;</td>
                        <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                        <td style="vertical-align: top; width: auto;">
                          <div style="text-align: justify;">902,445 shares of common stock issued after June 30, 2021;<br>
                          </div>
                        </td>
                      </tr>

                  </table>
                </div>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                      <td style="vertical-align: top; width: auto;">
                        <div style="text-align: justify;">7,783,029 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2021, at a weighted-average exercise price of $3.98 per share, of which no shares of common
                          stock were subsequently issued upon the exercise of stock options after June 30, 2021;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">99,000 shares of common stock issuable upon the exercise of stock options granted after June 30, 2021, with a weighted-average exercise price of $1.56 per share;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">686,133 shares of common stock issuable upon the vesting of restricted stock units (&#8220;RSUs&#8221;);</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">10,000 shares of common stock issuable upon the vesting of RSUs granted after June 30, 2021;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">4,528,160 shares of common stock issuable upon the exercise of warrants outstanding as of June 30, 2021, at a weighted-average exercise price of $2.82 per share; and</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman;">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">4,076,035 shares of common stock reserved for future awards under our equity incentive plans as of June 30, 2021.</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify;">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise of the outstanding options or warrants described above.</div>
      <div style="text-align: justify;"> <br>
      </div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic;">Investing in our common stock involves a high degree of risk. Before making an investment decision, you should carefully consider the risks described in this prospectus supplement and the
      accompanying prospectus, as well as other information we include or incorporate by reference in this prospectus supplement and the accompanying prospectus. In particular, you should carefully consider the information in Item 1A. &#8220;Risk Factors&#8221; as
      well as the factors listed under the heading &#8220;Forward-Looking Information,&#8221; in each case contained in our 2020 10-K and our Form 10-Q for the quarter ended June 30, 2021, which are incorporated by reference in this prospectus supplement. If any of
      these risks actually occur, our business, financial condition and results of operations could be affected negatively. In that event, the trading price of our common stock could decline and you could lose all or part of your investment. Additional
      risks and uncertainties that are not yet identified or that we do not believe are material may also affect our business, operating results and financial condition and could result in a complete loss of your investment.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-weight: bold;">Risks Relating to this Offering</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">Our management will have broad discretion to use the net proceeds from this offering, and our investment of these proceeds pending any such use may not yield a favorable return.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Our management will have broad discretion as to the use of the net proceeds from this offering by us and could use them for purposes other than those contemplated at the time of this offering. Accordingly, you will be
      relying on the judgment of our management with regard to the use of these net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. It is possible that the
      proceeds will be invested in a way that does not yield a favorable, or any, return for ADMA.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">You may experience future dilution as a result of future issuances of common stock, including through equity offerings.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The shares sold in this offering, if any, will be sold from time to time at various prices. However, we expect that the offering price of our common stock in this offering will be substantially higher than the net
      tangible book value per share of our outstanding common stock. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this
      offering. To the extent outstanding options are exercised, you will incur further dilution. Based on an assumed public offering price of $1.33 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on
      September 1, 2021, you will experience immediate dilution of $0.42 per share, representing the difference between our as adjusted net tangible book value per share after giving effect to this offering and the assumed public offering price.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price
      per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares of our common stock or other
      securities in the future could have rights superior to existing stockholders. The prices per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be
      higher or lower than the price per share paid by investors in this offering.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Future issuances of common stock could further depress the market for our common stock. We expect to continue to incur drug development and selling, general and administrative costs, and to satisfy our funding
      requirements, we will need to sell additional equity securities, which may include sales of significant amounts of common stock to strategic investors, and which common stock may be subject to registration rights. The sale or the proposed sale of
      substantial amounts of our common stock or other equity securities in the public markets or in private transactions may adversely affect the market price of our common stock and our stock price may decline substantially. Our stockholders may
      experience substantial dilution and a reduction in the price that they are able to obtain upon sale of their shares. Also, new equity securities issued may have greater rights, preferences or privileges than our existing common stock. In addition, we
      have a significant number of shares of restricted stock, restricted stock units, and stock options outstanding. To the extent that outstanding stock options have been or may be exercised or other shares issued, investors purchasing our common stock
      in this offering may experience further dilution.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">If we make one or more significant acquisitions in which the consideration includes stock or other securities, our stockholders&#8217; holdings may be significantly diluted. In addition, stockholders&#8217; holdings may also be
      diluted if we enter into arrangements with third parties permitting us to issue shares of common stock in lieu of certain cash payments upon the achievement of milestones.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common
      stock.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Sales of a substantial number of shares of our common stock in the public markets could depress the market price of our common stock, which could impair your ability to sell any shares of common stock that you purchase
      in this offering at prices above the price you pay in this offering and impair our ability to raise capital through the sale of additional equity securities. We cannot predict the effect that future sales of our common stock would have on the market
      price of our common stock.</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-style: italic; font-weight: bold;">We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We have never paid cash dividends on any of our capital stock and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and future
      debt agreements may preclude us from paying dividends. For example, the Perceptive Credit Agreement, by and between us and Perceptive Credit Holdings II, LP, as the lender and administrative agent, prohibits us from paying dividends. As a result,
      capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="USEOFPROCEEDS"><!--Anchor--></a>USE OF PROCEEDS</div>
    <div>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br>
    </div>
    <div style="text-align: justify;">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50,000,000 from time to time. Because there is no minimum offering amount required as a condition to close this offering, the
      actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We currently intend to use the net proceeds from any offering of our common stock under this prospectus for general corporate purposes, including procurement of raw materials, source plasma, supply chain initiatives
      and production expenditures, funding expansion of plasma centers, working capital, capital expenditures, expansion and resources for commercialization activities, and other potential research and development and business opportunities.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of commercial sales of BIVIGAM and ASCENIV, expansion of our manufacturing capacity and supply chain functions
      and any unforeseen cash needs. As a result, our management will have broad discretion in the application of the net proceeds. Pending the uses described above, we may invest the net proceeds from this offering in investment-grade, interest-bearing
      securities. We believe that the proceeds from the future sales of our common stock under our at-the-market offering facility will help provide the Company with the liquidity necessary to reach our expected $250 million in annual revenues beginning in
      2024 and potentially in excess of $300 million of annual revenue thereafter, as well as achieving profitability during the first quarter of 2024. We anticipate exiting 2021 approaching an annualized revenue run rate of approximately $100 million or
      more.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="DIVIDENDPOLICY"><!--Anchor--></a>DIVIDEND POLICY</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We have never declared or paid cash dividends on our capital stock and our current debt agreements preclude us from paying dividends. We currently intend to retain our future earnings, if any, for use in our business
      and therefore do not anticipate paying cash dividends in the foreseeable future. Payment of future dividends, if any, will be at the discretion of our Board after taking into account various factors, including our financial condition, operating
      results, current and anticipated cash needs and plans for expansion.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="DILUTION"><!--Anchor--></a>DILUTION</div>
    <div><br>
    </div>
    <div style="text-align: justify;">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public offering price per share of our common stock in this offering and the as
      adjusted net tangible book value per share of our common stock immediately after this offering.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">As of June 30, 2021, we had net tangible book value of approximately $106.0 million, or approximately $0.80 per share, based on an aggregate of 131,872,026 shares of our common stock outstanding as of that date.
      Historical net tangible book value per share represents the amount of total tangible assets, less total liabilities, divided by the outstanding number of shares of our common stock. Dilution in net tangible book value per share to new investors
      represents the difference between the amount per share paid by purchasers of shares of our common stock in this offering and the net tangible book value per share of our common stock immediately afterwards.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Without taking into account any other changes in net tangible book value after June 30, 2021, after giving effect to the assumed sale by us of shares of our common stock in the aggregate amount of $50,000,000 at an
      assumed public offering price of $1.33 per share, which was the last reported sale price of our common stock on The Nasdaq Global Market on September 1, 2021, and after deducting offering commissions and estimated offering expenses payable by us, our
      as adjusted net tangible book value at June 30, 2021 would have been approximately $154.3 million, or approximately $0.91 per share. This represents an immediate increase in net tangible book value of approximately $0.11 per share to existing
      stockholders and an immediate dilution in net tangible book value of $0.42 per share to investors in this offering. The following table illustrates this per share:</div>
    <div><br>
    </div>
    <table style="font-family: &#38;amp; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" id="z0e6153386c124a3d8c8974460bee85df" border="0" cellpadding="0" cellspacing="0">

        <tr>
          <td style="vertical-align: top; width: 80%;" valign="bottom">
            <div>Assumed public offering price per share</div>
          </td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; width: 8%;" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; width: 8%;" valign="bottom">
            <div>$1.33</div>
          </td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 80%;" valign="bottom">
            <div>Historical net tangible book value per share as of June 30, 2021</div>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 8%;" valign="bottom">
            <div>$0.80</div>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8%;" colspan="1" valign="bottom"><br>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 80%;" valign="bottom">
            <div>Increase in net tangible book value per share attributable to new investors</div>
          </td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; width: 8%;" valign="bottom">
            <div>$0.11</div>
          </td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 8%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 80%;" valign="bottom">
            <div>As adjusted net tangible book value per share after this offering</div>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); width: 8%;" colspan="1" valign="bottom"><br>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 8%;" valign="bottom">
            <div>$0.91</div>
          </td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 1%;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: top; width: 80%; padding-bottom: 4px;" valign="bottom">
            <div>Dilution per share to new investors purchasing shares in this offering</div>
          </td>
          <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; text-align: right; width: 8%; padding-bottom: 4px;" colspan="1" valign="bottom"><br>
          </td>
          <td style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
          <td style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" valign="bottom">&#160;</td>
          <td style="vertical-align: top; width: 8%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">
            <div>$0.42</div>
          </td>
          <td style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" nowrap="nowrap" valign="bottom">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify;">The number of shares of our common stock to be outstanding immediately after this offering is based on 131,872,026 shares of common stock outstanding as of June 30, 2021, and excludes:</div>
    <div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                  <td style="vertical-align: top; width: auto;">
                    <div style="text-align: justify;">902,445 shares of common stock issued after June 30, 2021;<br>
                    </div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zf49eb0332a504be79a8cf85624c21e4b" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="vertical-align: top; width: auto;">
                  <div style="text-align: justify;">7,783,029 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2021, at a weighted-average exercise price of $3.98 per share, of which no shares of common stock
                    were subsequently issued upon the exercise of stock options after June 30, 2021;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zaa5eb22bdba84b45b7ff1f38357272f2" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">99,000 shares of common stock issuable upon the exercise of stock options granted after June 30, 2021, with a weighted-average exercise price of $1.56 per share;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zaa9dfe89a8b64224b0223e12f8714da3" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">686,133 shares of common stock issuable upon the vesting of restricted stock units (&#8220;RSUs&#8221;);</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z55731d9033ce406baa1d8eba92690597" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">10,000 shares of common stock issuable upon the vesting of RSUs granted after June 30, 2021;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z4d2329911c6d48899c3d37d774e0372c" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">4,528,160 shares of common stock issuable upon the exercise of warrants outstanding as of June 30, 2021, at a weighted-average exercise price of $2.82 per share; and</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z1e5dce8b93c9485fb397467ea7ad64bd" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">4,076,035 shares of common stock reserved for future awards under our equity incentive plans as of June 30, 2021.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">To the extent that any of these outstanding options are exercised at prices per share below the public offering price per share in this offering or we issue additional shares under our equity incentive plans at prices
      below the public offering price per share in this offering, there will be further dilution to new investors.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that any
      options or warrants are exercised, new options are issued under our equity incentive plans, or we otherwise raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further
      dilution to new investors.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We have entered into a distribution agreement with Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;), under which we may offer and sell up to $50,000,000 of our shares of common stock from time to time through
      Raymond James acting as agent. Sales of our shares of common stock, if any, under this prospectus will be made by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act, including sales made
      directly on Nasdaq or any other trading market for our common stock. If authorized by us in writing, the agent may purchase shares of our common stock as principal.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Each time we wish to issue and sell our shares of common stock under the distribution agreement, we will notify Raymond James of the number of shares to be issued, the dates on which such sales are anticipated to be
      made, any limitation on the number of shares to be sold in any one day and any minimum price below which sales may not be made. Once we have instructed Raymond James, unless Raymond James declines to accept the terms of such notice, Raymond James has
      agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices to sell such shares up to the amount specified on such terms. The obligations of Raymond James under the distribution agreement to sell our
      shares of common stock are subject to a number of conditions that we must meet.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The settlement of sales of shares between us and Raymond James is generally anticipated to occur on the second trading day following the date on which the sale was made. Sales of our shares of common stock as
      contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Raymond James may agree upon. There is no arrangement for funds to be received in an escrow, trust or
      similar arrangement.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We will pay Raymond James a commission of up to 3.0% of the aggregate gross proceeds we receive from each sale of shares of common stock. Because there is no minimum offering amount required as a condition to close
      this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. In addition, we have agreed to reimburse Raymond James for the fees and disbursements of its counsel, payable upon
      execution of the distribution agreement, in an amount not to exceed $50,000, in addition to certain ongoing disbursements of its legal counsel. We estimate that the total expenses for the offering, excluding any commissions or expense reimbursement
      payable to Raymond James under the terms of the distribution agreement, will be approximately $140,000. The remaining sale proceeds, after deducting any other transaction fees, will equal our net proceeds from the sale of such shares.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">Raymond James will provide written confirmation to us before the open on The Nasdaq Global Market on the day following each day on which our shares of common stock are sold by Raymond James under the distribution
      agreement. Each confirmation will include the number of shares sold on that day, the aggregate gross proceeds of such sales and the proceeds to us.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">In connection with the sale of our shares of common stock on our behalf, Raymond James may be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act, and the compensation of Raymond James will be deemed
      to be underwriting commissions or discounts. We have agreed to indemnify Raymond James against certain civil liabilities, including liabilities under the Securities Act. We have also agreed to contribute to payments Raymond James may be required to
      make in respect of such liabilities.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The offering of our shares of common stock pursuant to the distribution agreement will terminate upon the earlier of (i) the sale of all shares of common stock subject to the distribution agreement and (ii) the
      termination of the distribution agreement as permitted therein. We and Raymond James may each terminate the distribution agreement at any time upon ten trading days&#8217; prior notice.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">This summary of the material provisions of the distribution agreement does not purport to be a complete statement of its terms and conditions. A copy of the distribution agreement is filed as an exhibit to a current
      report on Form 8&#8209;K under the Exchange Act which is incorporated by reference into this prospectus supplement.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: justify;">Raymond James and its affiliates may in the future provide various investment banking, commercial banking, financial advisory and other financial services for us and our affiliates, for which services they may in the
      future receive customary fees. In the course of its business, Raymond James may actively trade our securities for its own accounts or for the accounts of its respective customers, and, accordingly, Raymond James may at any time hold long or short
      positions in such securities.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">A prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Raymond James, and Raymond James may distribute the prospectus supplement and the
      accompanying prospectus electronically.</div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr style="margin-top: 4px; margin-bottom: 4px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;" noshade="noshade"></div>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The validity of the common stock offered by this prospectus will be passed upon for us by Morgan, Lewis &amp; Bockius LLP, Princeton, New Jersey. Raymond James is being represented by Mintz, Levin, Cohn, Ferris,
      Glovsky and Popeo, P.C., New York, New York.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The consolidated financial statements incorporated in this prospectus by reference from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 have been audited by CohnReznick LLP, an independent
      registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference, which report includes an explanatory paragraph on the Company&#8217;s ability to continue as a going concern. Such consolidated
      financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="WHEREYOUCANFINDMOREINFORM"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We have filed a registration statement on Form S-3 with the SEC for the shares of common stock offered by this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying
      prospectus, including the information incorporated by reference herein and therein, do not include all of the information contained in the registration statement. You should refer to the registration statement and its exhibits for additional
      information.</div>
    <div><br>
    </div>
    <div style="text-align: justify;">We file annual, quarterly and periodic reports, proxy statements and other information with the SEC. Many of our SEC filings are available to the public from the SEC&#8217;s website: www.sec.gov. We make available free of
      charge our annual, quarterly and current reports, proxy statements and other information upon request. To request such materials, please contact us at the following address or telephone number: ADMA Biologics, Inc. 465 Route 17, Ramsey, New Jersey
      07446, Attention: Brian Lenz, Executive Vice President and Chief Financial Officer, (201) 478-5552. Exhibits to the documents will not be sent, unless those exhibits have specifically been incorporated by reference in this prospectus. You may also
      obtain reports, statements or other information that we file with the SEC by accessing our website at www.admabiologics.com, under the Investors tab, SEC Filings. Information contained in, or accessible through, our website does not constitute a part
      of this prospectus.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-weight: bold;"><a name="INCORPORATIONOFCERTAINDOC"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div>
    <div><br>
    </div>
    <div style="text-align: justify;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information that is incorporated
      by reference is considered to be part of this prospectus, and the information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference into this prospectus the following documents:</div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="zf9450680b53f4a3c919c939d3fc3b88e" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000411/adma_10k.htm">March 25, 2021</a>;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z49d8b81d918c4d4387535917990693ea" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our definitive Proxy Statement on Schedule 14A for the 2021 Annual Meeting of Stockholders, filed <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121012041/nc10021493x2_def14a.htm">April








                      7, 2021</a> (solely to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020);</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z7946b55a08e340d686574365f57a481c" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2021 and June 30, 2021, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000657/adma_10q.htm">May 12, 2021</a> and <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121027950/brhc10027771_10q.htm">August 11, 2021</a>;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z911d98026e8a4212929562706033fa67" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">our Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000004/e620188_8k-adma.htm">January 4, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000045/e620209_8k-adma.htm">January 19, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000065/e620220_8k-adma.htm">January 26,
                      2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000106/e620239_8k-adma.htm">February 1, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000126/e620246_8k-adma.htm">February








                      3, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000299/e620325_8k-adma.htm">March 2, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000409/e620413_8k-adma.htm">March








                      25, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000549/e620523_8k-adma.htm">April 28, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000653/e620590_8k-adma.htm">May 12, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000749/e620651_8k-adma.htm">May 28, 2021</a>,
                    <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000751/e620652_8k-adma.htm">May 28, 2021</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001368514/000119380521000863/e620714_8k-adma.htm">June 14,
                      2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121024961/brhc10027069_8k.htm">July 20, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121025680/brhc10027259_8k.htm">July

                      27, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121027959/brhc10027958_8k.htm">August 12, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121027961/brhc10027960_8k.htm">August 12, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121028496/brhc10028121_8k.htm">August 16, 2021</a>
                    and <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121028679/brhc10028148_8k.htm">August 17, 2021</a> (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to
                    Form 8-K shall not be incorporated by reference into this prospectus); and</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div>
      <div>
        <div>
          <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" id="z56484bc235e54e3896989c0354990979" class="DSPFListTable" cellpadding="0" cellspacing="0">

              <tr style="vertical-align: top;">
                <td style="width: 36pt;">&#160;</td>
                <td style="vertical-align: top; width: 18pt;"><font style="font-family: Times New Roman">&#9679;</font></td>
                <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: justify;">the description of common stock set forth in Exhibit 4.11 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000411/adma_ex411.htm">March 25, 2021</a>, including any amendment or report filed for the purpose of updating such description.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">All documents subsequently filed with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering shall be deemed to be incorporated by reference into this prospectus
      supplement. Any statement contained in any document incorporated by reference herein will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any
      additional prospectus supplement modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus supplement.</div>
  </div>
  <div><br>
  </div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
    <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-size: 8pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">S-16</font></div>
    <div style="page-break-after: always;" id="DSPFPageBreak">
      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
  </div>
  <div>
    <div>
      <hr style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
    <div>
      <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman';">&#160;</font><font style="font-family: 'Times New Roman'; font-weight: bold;">PROSPECTUS</font></div>
      <div style="font-family: 'Times New Roman', Times, serif;"><font style="font-family: 'Times New Roman'; font-weight: bold;"> <br>
        </font></div>
      <div style="text-align: center;"><img src="ny20000594x1_424b5-image01.jpg"> </div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000;" align="center" noshade="noshade"></div>
      <div style="text-align: center; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; font-weight: bold;">$250,000,000</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Common Stock, Preferred Stock,</div>
      <div style="text-align: center; font-weight: bold;">Debt Securities, Warrants and Units</div>
      <div><br>
      </div>
      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;" align="center" noshade="noshade"> </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may offer from time to time in one or more offerings up to an aggregate of $250,000,000 of the common stock, preferred stock, debt securities, warrants or units described in this prospectus,
        separately or together in one or more combinations. The preferred stock, debt securities, and warrants may be convertible into or exercisable or exchangeable for common stock or preferred stock or other securities, as identified in the applicable
        prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus provides a general description of the securities we may offer. This prospectus will allow us to offer for sale securities over time. Each time we sell securities, we will provide
        specific terms of the securities offered in the applicable prospectus supplement. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free
        writing prospectus may add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by
        reference herein and therein, before you invest in any of our securities. This prospectus may not be used to sell the securities unless accompanied by a prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may offer and sell the securities through underwriters, dealers or agents, or directly to purchasers, or through a combination of these methods. See &#8220;Plan of Distribution&#8221; beginning on page 16
        of this prospectus.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; On May 26, 2021, the last reported sale price of our common stock was $1.72 per share.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-weight: bold;">Investing in our securities involves risk. See &#8220;Risk Factors&#8221; beginning on page 5 of this prospectus. You should carefully read this prospectus, the applicable prospectus
        supplement and any related free writing prospectus, as well as the documents incorporated by reference herein and therein, before you invest in any of our securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-weight: bold;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or
        complete. Any representation to the contrary is a criminal offense.</div>
      <div style="text-align: justify; font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-weight: bold;">
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 2px; width: 20%; color: #000000; text-align: center;" align="center" noshade="noshade"> </div>
      <div><br>
      </div>
      <div style="text-align: center;">The date of this prospectus is May 28, 2021</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;">TABLE OF CONTENTS</div>
      <div><br>
      </div>
      <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" border="0" cellpadding="0" cellspacing="0">

          <tr>
            <td style="width: 96%; vertical-align: top;">&#160;</td>
            <td style="width: 4%; vertical-align: top;">
              <div style="text-align: right; font-weight: bold;">Page</div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#ABOUTTHISPROSPECTUS">About This Prospectus</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#ABOUTTHISPROSPECTUS">2</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#THECOMPANY">The Company</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#THECOMPANY">3</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#RISKFACTORS-2">Risk Factors</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#RISKFACTORS-2">5</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#SPECIALNOTEREGARDINGFORWA">Special Note Regarding Forward-Looking Statements</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#SPECIALNOTEREGARDINGFORWA">6</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#USEOFPROCEEDS-2">Use of Proceeds</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#USEOFPROCEEDS-2">8</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#DESCRIPTIONOFTHESECURITIE">Description of the Securities We May Offer</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#DESCRIPTIONOFTHESECURITIE">9</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-left: 18pt;"><a href="#DESCRIPTIONOFCAPITALSTOCK">Description of Capital Stock</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#DESCRIPTIONOFCAPITALSTOCK">9</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div style="margin-left: 18pt;"><a href="#DESCRIPTIONOFDEBTSECURITI">Description of Debt Securities</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#DESCRIPTIONOFDEBTSECURITI">12</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-left: 18pt;"><a href="#DESCRIPTIONOFWARRANTS">Description of Warrants</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#DESCRIPTIONOFWARRANTS">12</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div style="margin-left: 18pt;"><a href="#DESCRIPTIONOFUNITS">Description of Units</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#DESCRIPTIONOFUNITS">12</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#LEGALOWNERSHIPOFSECURITIE">Legal Ownership of Securities</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#LEGALOWNERSHIPOFSECURITIE">12</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#PLANOFDISTRIBUTION-2">Plan of Distribution</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#PLANOFDISTRIBUTION-2">16</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#WHEREYOUCANFINDMOREINFORM-2">Where You Can Find More Information</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#WHEREYOUCANFINDMOREINFORM-2">19</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#INCORPORATIONOFCERTAINDOC-2">Incorporation of Certain Documents by Reference</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#INCORPORATIONOFCERTAINDOC-2">19</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div><a href="#LEGALMATTERS-2">Legal Matters</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255);">
              <div><a href="#LEGALMATTERS-2">20</a></div>
            </td>
          </tr>
          <tr>
            <td style="width: 96%; vertical-align: top;">
              <div><a href="#EXPERTS-2">Experts</a></div>
            </td>
            <td style="width: 4%; vertical-align: bottom; text-align: right;">
              <div><a href="#EXPERTS-2">20</a></div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus is part of a registration statement that we have filed with the Securities and Exchange Commission (the &#8220;SEC&#8221; or the &#8220;Commission&#8221;) using a &#8220;shelf&#8221; registration process under the
        Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Under this shelf registration process, we may offer and sell, from time to time, any combination of the securities described in this prospectus in one or more offerings up to a total dollar
        amount of $250,000,000.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus provides a general description of the securities we may offer. Each time we sell the securities, we will, to the extent required by law, provide a prospectus supplement that will
        contain specific information about the terms of the offering. We may also authorize one or more free writing prospectuses to be provided to you in connection with the offering. The prospectus supplement and any related free writing prospectus may
        add, update or change information contained in this prospectus. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the securities, you should refer to
        the registration statement, including its exhibits. You should carefully read this prospectus, the applicable prospectus supplement, and any applicable free writing prospectus, as well as the information and documents incorporated herein and
        therein by reference and the additional information under the heading &#8220;Where You Can Find More Information,&#8221; before making an investment decision.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We have not authorized any dealer, salesman or other person to give any information or to make any representation other than those contained in, or incorporated by reference into, this prospectus
        and the applicable prospectus supplement, and any free writing prospectus we have authorized for use in connection with a specific offering.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus and any accompanying prospectus supplement to this prospectus do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the registered
        securities to which they relate, nor do this prospectus or any accompanying prospectus supplement to this prospectus constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction to any person to whom it is
        unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information contained in this prospectus, any accompanying prospectus supplement and any applicable free writing prospectus is accurate on any date
        subsequent to the date set forth on the front of the document or that any information we have incorporated by reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus, any
        accompanying prospectus supplement or any applicable free writing prospectus is delivered, or securities sold, on a later date.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus may not be used by us to consummate sales of our securities unless it is accompanied by a prospectus supplement. To the extent there are inconsistencies between any prospectus
        supplement, this prospectus and any documents incorporated by reference, the document with the most recent date will control.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus supplement includes our trademarks, trade names and service marks, such as &#8220;BIVIGAM<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,&#8221; &#8220;ASCENIV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup>&#8221; and &#8220;Nabi-HB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,&#8221; which are protected under applicable intellectual property laws and
        are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this prospectus supplement may appear without the <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup> or <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> symbols, but such references are not
        intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of
        other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Unless the context otherwise requires, references in this prospectus to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company,&#8221; &#8220;ADMA Biologics&#8221; and &#8220;ADMA&#8221; refer to ADMA Biologics, Inc., a Delaware corporation, and its
        subsidiaries: ADMA BioCenters Georgia Inc., a Delaware corporation (&#8220;ADMA BioCenters&#8221;), ADMA BioManufacturing, LLC, a Delaware limited liability company (&#8220;ADMA BioManufacturing&#8221;), and ADMA Plasma Biologics, Inc., a Delaware corporation (&#8220;ADMA
        Plasma&#8221;).</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-2-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="THECOMPANY"><!--Anchor--></a>THE COMPANY</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our Business</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We are an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at
        risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical
        reasons.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i) BIVIGAM (Immune Globulin
        Intravenous, Human), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;), and for which we received FDA approval on May 9,
        2019 and commenced commercial sales in August 2019; (ii) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an IVIG product indicated for the treatment of PI, for which we received FDA approval on April 1, 2019 and commenced first
        commercial sales in October 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of
        plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection for an immunoglobulin manufactured to
        contain standardized antibodies to numerous serotypes of S. pneumoniae. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious
        diseases.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters
        (the &#8220;Boca Facility&#8221;). Based on current production yields, our ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce quantities of our immune globulin (&#8220;IG&#8221;) products with
        potentially significant increased revenues beginning in 2024 and thereafter, as well as potentially achieving profitability during the first quarter of 2024, as we ramp-up production over the next three to five years.</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate FDA-licensed source plasma collection facilities in the U.S. This business unit, which we refer to as our Plasma Collection Centers business segment,
        provides us with a portion of our blood plasma for the manufacture of our products and product candidates, and also allows us to sell certain quantities of source plasma to customers for further manufacturing. As a part of our planned supply chain
        robustness initiative, we have opened three new plasma collection centers during the last 15 months, and we now have seven plasma collection centers in various stages of approval and development, including four that are fully operational and
        collecting plasma. With respect to our fully operational plasma collection centers, two centers currently hold FDA licenses, a third has a Biologics License Application (&#8220;BLA&#8221;) pending an FDA decision expected in the fourth quarter of 2021, and we
        anticipate submitting a fourth BLA filing for our newest plasma collection center in the third quarter of 2021. In addition, one of our FDA-approved plasma collection centers also has approvals from the Korean Ministry of Food and Drug Safety
        (&#8220;MFDS&#8221;), as well as FDA approval to implement a Hepatitis B immunization program. After giving effect to the progress we made in 2020 and thus far in 2021 with our plasma collection network expansion, we believe we remain on track to achieve our
        goal of having 10 or more plasma collection centers operating in the U.S. by 2024. A typical plasma collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may
        be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products or product candidates is
        sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221; market.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic; font-weight: bold;">Corporate Information</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">ADMA Biologics, Inc. was founded on June 24, 2004 as a New Jersey corporation and re-incorporated in Delaware on July 16, 2007. We operate through our wholly-owned subsidiaries, ADMA BioCenters,
        ADMA BioManufacturing, and ADMA Plasma Biologics.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-3-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We maintain our headquarters at 465 State Route 17 South, Ramsey, NJ 07446. Our telephone number is (201) 478-5552. Our Florida campus is located at 5800 Park of Commerce Boulevard, Northwest, Boca
        Raton, FL 33487. The Florida telephone number is (561) 989-5800. We maintain a website at www.admabiologics.com; however, the information on, or that can be accessed through, our website is not part of this prospectus supplement. This prospectus
        supplement and all of our filings under the Exchange Act, including copies of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, are available free of charge through our
        website on the date we file those materials with, or furnish them to, the SEC. Such filings are also available to the public on the SEC&#8217;s website at www.sec.gov.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-4-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="RISKFACTORS-2"><!--Anchor--></a>RISK FACTORS</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">Investing in our securities involves risks. Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate by reference in this prospectus. In
        particular, you should carefully consider the information under the heading &#8220;Risk Factors,&#8221; as well as the factors listed under the heading &#8220;Special Note Regarding Forward-Looking Statements,&#8221; in each case contained in our Annual Report on Form
        10-K for our most recent fiscal year, in any Quarterly Reports on Form 10-Q that have been filed since our most recent Annual Report on Form 10-K and in any other documents that we file with the SEC under the Exchange Act, each of which is
        incorporated by reference in this prospectus. New risks may emerge in the future at any time, and we cannot predict such risks or estimate the extent to which they may affect our financial condition or performance. The prospectus supplement
        applicable to a specific offering may contain a discussion of additional risks applicable to an investment in us and our securities we are offering under that prospectus supplement. Each of the risks described could result in a decrease in the
        value of the securities and your investment therein.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-5-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="SPECIALNOTEREGARDINGFORWA"><!--Anchor--></a>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus and the documents incorporated by reference into this prospectus and any prospectus supplement or free writing prospectus may contain &#8220;forward-looking statements&#8221; within the meaning
        of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). These forward-looking statements only provide our current expectations or forecasts of future events and financial
        performance and may be identified by the use of such terms as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;will&#8221; or &#8220;should,&#8221; &#8220;could,&#8221; &#8220;predicts&#8221; or the negative thereof, or other variations or comparable
        terminology, though the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts and include, without limitation, statements concerning
        our business strategy, outlook, objectives, future milestones, plans, intentions, goals, and future financial condition, including the period of time for which our existing resources will enable us to fund our operations.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">You should read carefully the risks described in the section entitled &#8220;Risk Factors&#8221; beginning on page 5 of this prospectus, and in any accompanying prospectus supplement or related free writing
        prospectus, together with all information incorporated by reference herein and therein, to better understand the significant risks and uncertainties inherent in our business and underlying any forward-looking statements. Our actual results could
        differ materially from those contained in the forward-looking statements due to the factors described in the section entitled &#8220;Risk Factors&#8221; beginning on page 5 of this prospectus; in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s
        Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s most recent Annual Report on Form 10-K; and in the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s most recent Quarterly Report on Form 10-Q. These
        statements include statements about our ability to continue as a going concern; our ability to manufacture BIVIGAM and ASCENIV on a commercial scale and commercialize these products as a result of their approval by the U.S. Food and Drug
        Administration (the &#8220;FDA&#8221;) in 2019; our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts; the safety, efficacy and expected
        timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the labeling or nature of any such approvals; the achievement of or expected timing, progress and results of clinical
        development, clinical trials and potential regulatory approvals for our product candidates; our dependence upon our third-party customers and vendors and their compliance with applicable regulatory requirements; our belief that we have addressed
        the delays experienced with final drug product Good Manufacturing Practices (&#8220;GMP&#8221;) release testing by our third-party vendors by adding additional release testing laboratories to our FDA-approved consortium listed in our drug approval documents;
        our ability to obtain adequate quantities of FDA-approved plasma with proper specifications; our plans to increase our supplies of source plasma, which include plasma collection center expansion and reliance on third-party supply agreements as well
        as any extensions to such agreements; the potential indications for our products and product candidates; potential investigational new product applications; the acceptability of any of our products, including BIVIGAM, ASCENIV and Nabi-HB, for any
        purpose, including FDA-approved indications, by physicians, patients or payers; our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses; Federal, state and local regulatory and
        business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions; concurrence by the FDA with our conclusions concerning our products and product candidates; the comparability of results
        of our hyperimmune and immune globulin products to other comparably run hyperimmune and immune globulin clinical trials; the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with Primary Immune
        Deficiency Disease, Primary Humoral Immunodeficiency Disease or other immune deficiencies or any other condition for which the products may be prescribed or evaluated; our ability to market and promote Nabi-HB in a highly competitive environment
        with increasing competition from other antiviral therapies and to generate meaningful revenues from this product; our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with
        respect to ASCENIV or other future pipeline product candidates; our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy; our plans related to the expansion of our manufacturing capacity, yield
        improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and other collaborative agreements and the success of such endeavors; our estimates regarding revenues, expenses, capital requirements, timing to profitability
        and the need for and availability of additional financing; possible or likely reimbursement levels for our currently marketed products; estimates regarding market size, projected growth and sales of our existing products as well as our expectations
        of market acceptance of ASCENIV and BIVIGAM; effects of the coronavirus COVID-19 pandemic on our business, financial condition, liquidity and results of operations, and our ability to continue operations in the same manner as previously conducted
        prior to the macroeconomic effects of the COVID-19 pandemic; future domestic and global economic conditions or performance; and expectations for future capital requirements. There can be no assurance that the forward-looking statements included in
        this document will prove to be accurate.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-6-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Any forward-looking statements that we make in this prospectus speak only as of the date of such statements and we undertake no obligation to publicly update any forward-looking statements or to
        publicly announce revisions to any of the forward-looking statements, whether as a result of new information, future events or otherwise, except as may otherwise be required by the federal securities laws.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-7-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="USEOFPROCEEDS-2"><!--Anchor--></a>USE OF PROCEEDS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Unless the applicable prospectus supplement states otherwise, we anticipate that the net proceeds from our sale of any securities will be used for general corporate purposes, including procurement
        of raw materials, source plasma, supply chain initiatives and production expenditures, funding expansion of plasma centers, working capital, capital expenditures, expansion and resources for commercialization activities, and other potential
        research and development and business opportunities.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-8-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFTHESECURITIE"><!--Anchor--></a>DESCRIPTION OF THE SECURITIES WE MAY OFFER</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The descriptions of the securities contained in this prospectus summarize the material terms and provisions of the various types of securities that we may offer. We will describe in the applicable
        prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate in the applicable prospectus supplement, the terms of the securities may differ from the terms we have
        summarized below. We will also include in the prospectus supplement information, where applicable, about material U.S. federal income tax considerations relating to the securities, and the securities exchange, if any, on which the securities will
        be listed.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may offer and sell from time to time, in one or more primary offerings, our common stock, preferred stock, debt securities, warrants or units, or any combination of the foregoing.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In this prospectus, we refer to the common stock, preferred stock, debt securities, warrants or units, or any combination of the foregoing securities to be sold by us in a primary offering
        collectively as &#8220;securities.&#8221; The total dollar amount of all securities that we may issue under this prospectus will not exceed $250,000,000.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">This prospectus may not be used by us to consummate a sale of securities unless it is accompanied by a prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFCAPITALSTOCK"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The following description of our common stock and preferred stock, together with the additional information we include in the applicable prospectus supplement, summarizes the material terms and
        provisions of the common stock and preferred stock that we may offer under this prospectus. It may not contain all the information that is important to you. For the complete terms of our common stock and preferred stock, please refer to our Second
        Amended and Restated Certificate of Incorporation (the &#8220;Certificate of Incorporation&#8221;) and our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;).</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">General</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The total number of shares of capital stock that the Company has authority to issue is 310,000,000, divided into two classes consisting of (i) 300,000,000 shares of common stock, $0.0001 par value
        per share and (ii) 10,000,000 shares of preferred stock, $0.0001 par value per share.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">As of March 31, 2021, 123,044,981 shares of common stock were issued and outstanding and an additional 13,362,319 shares were issuable upon exercise of outstanding options and warrants or upon the
        vesting of restricted stock units (&#8220;RSUs&#8221;). Of those 13,362,319 shares of common stock issuable upon exercise of outstanding options and warrants or vesting of RSUs, 10,258,466 shares are issuable to officers and directors and principal
        stockholders of the Company, 2,575,693 shares are issuable to other employees and third-party consultants to the Company and 528,160 shares are issuable to former noteholders of the Company.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">As of March 31, 2021, no shares of preferred stock were issued and outstanding.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Common Stock</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Voting</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The holders of common stock are entitled to one vote per share on all matters on which stockholders are generally entitled to vote. The holders of a majority of the outstanding shares of common
        stock constitute a quorum at a meeting of stockholders for the transaction of any business. Directors are elected by a plurality of the votes of the shares present in person or represented by proxy at the meeting and entitled to vote on the
        election of directors. Any other action is authorized by a majority of the votes cast, except where the Delaware General Corporation Law (&#8220;DGCL&#8221;) prescribes a different percentage of votes and/or a different exercise of voting power.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-9-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; font-style: italic;">Dividends</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Subject to applicable law and the rights, if any, of the holders of any outstanding series of preferred stock, dividends may be declared and paid on the common stock out of funds legally available
        therefor at such times and in such amounts as the Company&#8217;s board of directors (the &#8220;Board&#8221;), in its discretion, shall determine.</div>
      <div><br>
      </div>
      <div style="text-align: justify; font-style: italic;">Distributions upon Dissolution, Liquidation or Winding Up</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Upon a liquidation, dissolution or windup of the Company, subject to the rights, if any, of the holders of any outstanding series of preferred stock, the holders of the common stock shall be
        entitled to receive the assets of the Company available for distribution to its stockholders ratably in proportion to the number of shares of common stock held by them. The holders of common stock do not have cumulative or preemptive rights.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Preferred Stock</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">No shares of preferred stock are currently outstanding, and the Company has no current plans to issue preferred stock. The issuance of shares of preferred stock, or the issuance of rights to
        purchase preferred stock, could be used to discourage an unsolicited acquisition proposal. For example, a business combination could be impeded by the issuance of a series of preferred stock containing class voting rights that would enable the
        holder or holders of such series to block any such transaction. Alternatively, a business combination could be facilitated by the issuance of a series of preferred stock having sufficient voting rights to provide a required percentage vote of the
        Company&#8217;s stockholders. In addition, under some circumstances, the issuance of preferred stock could adversely affect the voting power and other rights of the holders of common stock. Although prior to issuing any series of preferred stock the
        Board is required to make a determination as to whether the issuance is in the best interests of the Company&#8217;s stockholders, the Board could act in a manner that would discourage an acquisition attempt or other transaction that some, or a majority,
        of the stockholders might believe to be in their best interests or in which the stockholders might receive a premium for their stock over prevailing market prices of such stock. The Board does not presently intend to seek stockholder approval prior
        to any issuance of currently authorized preferred stock, unless otherwise required by law or applicable stock exchange requirements.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Warrants</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">On February 11, 2019, the Company issued to Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;) a warrant to purchase 1,360,000 shares of our common stock at an exercise price of $3.28 per share (the
        &#8220;Original Perceptive Warrant&#8221;). The Original Perceptive Warrant became exercisable on the date of issuance and was valued at $2.7 million. The Original Perceptive Warrant was valued using the Black-Scholes option-pricing model assuming an expected
        term of 10 years, a volatility of 61.2%, a dividend yield of 0% and a risk-free interest rate of 2.65%.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">On May 3, 2019, the Company issued to Perceptive a warrant to purchase an aggregate of 250,000 shares of common stock at an exercise price of $4.64 per share (the &#8220;Perceptive Tranche III Warrant&#8221;).
        The Perceptive Tranche III Warrant was exercisable on the date of issuance and was valued at $0.9 million. The Perceptive Tranche III Warrant was valued using the Black-Scholes option-pricing model assuming an expected term of 10 years, a
        volatility of 62.3%, a dividend yield of 0% and a risk-free interest rate of 2.54%.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">On December 8, 2020, the Company issued to Perceptive a warrant to purchase an aggregate of 2,390,000 shares of common stock at an exercise price $1.94 per share (the &#8220;Perceptive Tranche IV
        Warrant&#8221;). The Perceptive Tranche IV Warrant was valued at $3.7 million, using the Black-Scholes option-pricing model assuming an expected term of 10 years, a volatility of 69.3%, a dividend yield of 0% and a risk-free interest rate of 0.92%.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Registration Rights</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In connection with our acquisition of certain assets of Biotest Pharmaceuticals Corporation (&#8220;BPC&#8221;) in June 2017 (the &#8220;Biotest Transaction&#8221;), we entered into a registration rights agreement with
        BPC pursuant to which BPC, or its transferee, or its affiliate(s) have, among other things, certain registration rights under the Securities Act of 1933, as amended, with respect to its shares of our Common Stock, subject to certain transfer
        restrictions. In July 2018, BPC agreed to transfer its remaining shares of Common Stock to The Biotest Divestiture Trust (the &#8220;Biotest Trust&#8221;). In connection with the transfer of shares, the Biotest Trust has agreed to be bound by all obligations
        of, and will have all of the remaining rights of BPC under the aforementioned registration rights agreement.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-10-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;">Indemnification of Directors and Officers</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Company&#8217;s directors and officers are indemnified as provided by the DGCL, the Company&#8217;s Certificate of Incorporation, and the Company&#8217;s Bylaws. The Company has been advised that, in the opinion
        of the SEC, indemnification for liabilities arising under the Securities Act is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities is
        asserted by one of the Company&#8217;s directors, officers, or controlling persons in connection with the securities being registered, the Company will, unless in the opinion of its legal counsel the matter has been settled by controlling precedent,
        submit the question of whether such indemnification is against public policy to a court of appropriate jurisdiction. The Company will then be governed by the court&#8217;s decision.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We are party to indemnification agreements with each of our directors and officers. These agreements require us to, among other things, indemnify our directors and officers against certain
        liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by applicable laws. These indemnification provisions and the indemnification agreements are sufficiently broad to permit
        indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act. The Company also maintains director and officer liability insurance.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Delaware Anti-Takeover Law; Stockholder Rights Agreement</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Company is subject to the provisions of Section 203 of the DGCL. Section 203 prohibits publicly held Delaware corporations from engaging in a &#8220;business combination&#8221; with an &#8220;interested
        stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes mergers, asset
        sales and other transactions resulting in a financial benefit to the interested stockholder. Subject to certain exceptions, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years did own,
        15% or more of the corporation&#8217;s voting stock. These provisions could have the effect of delaying, deferring or preventing a change of control of the Company or reducing the price that certain investors might be willing to pay in the future for
        shares of the Company&#8217;s stock.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Our Board has also adopted a short-term stockholder rights agreement with an expiration date of December 15, 2021 and an ownership trigger threshold of 10%. This stockholder rights agreement could
        render more difficult or discourage a merger, tender offer or assumption of control of the Company that is not approved by our Board. The rights agreement, however, should not interfere with any merger, tender or exchange offer or other business
        combination approved by our Board. In addition, the rights agreement does not prevent our Board from considering any offer that it considers to be in the best interest of the Company&#8217;s stockholders.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Staggered Board; Removal of Directors; Certificate of Incorporation</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Company&#8217;s Certificate of Incorporation divides the Company&#8217;s Board into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of the
        Company&#8217;s stockholders, with the other classes continuing for the remainder of their respective three-year terms. Except as the DGCL may otherwise require, any newly created directorships or vacancies on the Board may be filled only by the Board,
        but subject to the rights of holders of any series of preferred stock and to the terms and conditions of the Stockholders Agreement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The Company&#8217;s Certificate of Incorporation provides that (i) all stockholder actions must be effected at a duly called meeting of the stockholders and (ii) stockholders may not adopt actions by
        written consent without a meeting.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The combination of these provisions will make it more difficult for the Company&#8217;s existing stockholders to replace the Board as well as for another party to obtain control of the Company by
        replacing the Board. Since the Board has the power to retain and discharge the officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization
        of undesignated preferred stock makes it possible for the Board to issue preferred stock with voting or other rights or preferences that could impede any attempt to effect a change of control of the Company.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-11-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;">Transfer Agent</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Continental Stock Transfer &amp; Trust Company, 17 Battery Place, New York, New York, serves as the transfer agent and registrar for the Company&#8217;s stock.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFDEBTSECURITI"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may issue from time to time, in one or more offerings, senior or subordinated debt securities covered by this prospectus. When we offer to sell a particular series of debt securities, we will
        describe the specific terms of the series in the applicable prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFWARRANTS"><!--Anchor--></a>DESCRIPTION OF WARRANTS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may issue warrants to purchase our debt or equity securities or other rights, including rights to receive payment in cash or securities based on the value, rate or price of one or more specified
        commodities, currencies, securities or indices, or any combination of the foregoing. Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of warrants will
        be issued under a separate warrant agreement to be entered into between us and a warrant agent. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the
        applicable prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="DESCRIPTIONOFUNITS"><!--Anchor--></a>DESCRIPTION OF UNITS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">As specified in the applicable prospectus supplement, we may issue units consisting of warrants, debt securities, shares of preferred stock, shares of common stock or any combination of such
        securities.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="LEGALOWNERSHIPOFSECURITIE"><!--Anchor--></a>LEGAL OWNERSHIP OF SECURITIES</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities
        registered in their own names on the books that we or any applicable trustee maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through
        others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form
        or in street name will be indirect holders.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Book-Entry Holders</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in
        the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn,
        hold beneficial interests in the securities on behalf of themselves or their customers.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its
        nominee. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it
        receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not
        obligated to do so under the terms of the securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial
        institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-12-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;">Street Name Holders</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by
        an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains
        at that institution.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">For securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those
        securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or
        because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Legal Holders</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have
        obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are
        issuing the securities only in global form.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that holder is required, under agreements with depositary
        participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our
        obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the holders contact the
        indirect holders is up to the holders.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Special Considerations for Indirect Holders</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If you hold securities through a bank, broker or other financial institution, either in book-entry form or in street name, you should check with your own institution to find out:</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">how it handles securities payments and notices;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">whether it imposes fees or charges;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">how it would handle a request for the holders&#8217; consent, if ever required;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">if the securities are in book entry form, how the depositary&#8217;s rules and procedures will affect these matters.</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-13-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="font-weight: bold;">Global Securities</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">A global security is a security held by a depositary that represents one or any other number of individual securities. Generally, all securities represented by the same global securities will have
        the same terms.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Each security issued in book-entry form will be represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The
        financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, The Depository Trust Company (&#8220;DTC&#8221;) will be the depositary for all securities issued in book-entry
        form.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We
        describe those situations below under &#8220;&#8212;Special Situations When a Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by
        a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with
        the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless
        and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Special Considerations for Global Securities</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">As an indirect holder, an investor&#8217;s rights relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general
        laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If securities are issued only in the form of a global security, an investor should be aware of the following:</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non global certificates for his or her interest in the securities, except in the special situations we
                          describe below;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="vertical-align: top;">
                        <div style="text-align: left;">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the securities and protection of his or her legal rights relating to the securities, as we describe
                          under &#8220;&#8212;Legal Holders&#8221; above;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book entry form;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of
                          the pledge in order for the pledge to be effective;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in a global security. We and any
                          applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in a global security. We and the trustee also do not supervise the depositary in any way;</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book entry system use immediately available funds, and your
                          broker or bank may require you to do so as well; and</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-14-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div>
        <div>
          <div>
            <div>
              <div>
                <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                    <tr style="vertical-align: top;">
                      <td style="width: 36pt;">&#160;</td>
                      <td style="vertical-align: top; width: 18pt;">
                        <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                      </td>
                      <td style="align: left; vertical-align: top; width: auto;">
                        <div style="text-align: left;">financial institutions that participate in the depositary&#8217;s book entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting
                          payments, notices and other matters relating to the securities. There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those
                          intermediaries.</div>
                      </td>
                    </tr>

                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Special Situations When a Global Security Will Be Terminated</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange,
        the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in securities transferred to their own name, so that they will
        be direct holders. We have described the rights of holders and street name investors above.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The global security will terminate when the following special situations occur:</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div>if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div>if we notify any applicable trustee that we wish to terminate that global security; or</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" class="DSPFListTable" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div>if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived.</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the prospectus supplement.
        When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-15-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="PLANOFDISTRIBUTION-2"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may offer securities under this prospectus from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these methods or through
        underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions:</div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">at a fixed price or prices, which may be changed;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="vertical-align: top;">
                    <div style="text-align: left;">at market prices prevailing at the time of sale;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">at prices related to such prevailing market prices; or</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">at negotiated prices.</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Each time that securities covered by this prospectus are offered, we will provide a prospectus supplement or supplements that will describe the method of distribution and set forth the terms and
        conditions of the offering of such securities, including the offering price of the securities and the proceeds to us.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the securities from time to time. Any agent
        involved in the offer or sale of our securities will be identified in a prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If a dealer is utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the
        public at varying prices to be determined by the dealer at the time of resale.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the underwriter at the time of sale and the name of any
        underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we, or the purchasers of securities for whom the underwriter may
        act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or
        commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best efforts basis and a dealer will purchase securities
        as a principal, and may then resell the securities at varying prices to be determined by the dealer.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions allowed by underwriters to participating
        dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and
        commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against civil
        liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The securities may or may not be listed on a national securities exchange. To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that
        stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In
        these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of
        the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are repurchased in
        connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be
        discontinued at any time.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-16-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">If indicated in the applicable prospectus supplement, underwriters or other persons acting as agents may be authorized to solicit offers by institutions or other suitable purchasers to purchase the
        securities at the public offering price set forth in the prospectus supplement, pursuant to delayed delivery contracts providing for payment and delivery on the date or dates stated in the prospectus supplement. These purchasers may include, among
        others, commercial and savings banks, insurance companies, pension funds, investment companies and educational and charitable institutions. Delayed delivery contracts will be subject to the condition that the purchase of the securities covered by
        the delayed delivery contracts will not at the time of delivery be prohibited under the laws of any jurisdiction in the United States to which the purchaser is subject. The underwriters and agents will not have any responsibility with respect to
        the validity or performance of these contracts.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. The terms of such &#8220;at the market offerings&#8221; will be set forth in
        the applicable prospectus supplement. We may engage an agent to act as a sales agent in such &#8220;at the market offerings&#8221; on a best efforts basis using commercially reasonable efforts consistent with normal trading and sales practices, on mutually
        agreed terms between such agent and us. We will name any agent involved in such &#8220;at the market offerings&#8221; of securities and will list commissions payable by us to these agents in the applicable prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable
        prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may
        use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open
        borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise
        loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its
        economic short position to investors in our securities or in connection with a concurrent offering of other securities.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The specific terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">General Information</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Underwriters, dealers and agents that participate in the distribution of our securities may be underwriters as defined in the Securities Act, and any discounts or commissions they receive and any
        profit they make on the resale of the offered securities may be treated as underwriting discounts and commissions under the Securities Act. Any underwriters or agents will be identified and their compensation described in a prospectus supplement.
        We may indemnify agents, underwriters, and dealers against certain civil liabilities, including liabilities under the Securities Act, or make contributions to payments they may be required to make relating to those liabilities. Our agents,
        underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Each series of securities offered by this prospectus may be a new issue of securities with no established trading market. Any underwriters to whom securities offered by this prospectus are sold by
        us for public offering and sale may make a market in the securities offered by this prospectus, but the underwriters will not be obligated to do so and may discontinue any market making at any time without notice. No assurance can be given as to
        the liquidity of the trading market for any securities offered by this prospectus.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-17-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Representatives of the underwriters through whom our securities are sold for public offering and sale may engage in over-allotment, stabilizing transactions, syndicate short covering transactions
        and penalty bids in accordance with Regulation M under the Exchange Act. Over-allotment involves syndicate sales in excess of the offering size, which creates a syndicate short position. Stabilizing transactions permit bids to purchase the offered
        securities so long as the stabilizing bids do not exceed a specified maximum.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Syndicate covering transactions involve purchases of the offered securities in the open market after the distribution has been completed in order to cover syndicate short positions. Penalty bids
        permit the representative of the underwriters to reclaim a selling concession from a syndicate member when the offered securities originally sold by such syndicate member are purchased in a syndicate covering transaction to cover syndicate short
        positions. Such stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the offered securities to be higher than it would otherwise be in the absence of such transactions. These transactions may be effected
        on a national securities exchange and, if commenced, may be discontinued at any time.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">Underwriters, dealers and agents may be customers of, engage in transactions with or perform services for, us and our subsidiaries in the ordinary course of business.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We will bear all costs, expenses and fees in connection with the registration of the securities as well as the expense of all commissions and discounts, if any, attributable to the sales of any of
        our securities by us.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-18-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="WHEREYOUCANFINDMOREINFORM-2"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">We file annual, quarterly and periodic reports, proxy statements and other information with the SEC. Many of our SEC filings are available to the public from the SEC&#8217;s website: www.sec.gov. We make
        available free of charge our annual, quarterly and current reports, proxy statements and other information upon request or such reports are available on the Company&#8217;s website at www.admabiologics.com. To access or request such materials, please
        visit www.admabiologics.com or contact us at the following address or telephone number: ADMA Biologics, Inc. 465 Route 17 South, Ramsey, New Jersey 07446, Attention: Brian Lenz, Executive Vice President and Chief Financial Officer, (201) 478-5552.
        Exhibits to the documents will not be sent, unless those exhibits have specifically been incorporated by reference in this prospectus.</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">You may also obtain reports, statements or other information that we file with the SEC by accessing our website at www.admabiologics.com, under the Investors tab, SEC Filings. Information contained
        in, or accessible through, our website does not constitute a part of this prospectus or any accompanying prospectus supplement.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="INCORPORATIONOFCERTAINDOC-2"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information
        that is incorporated by reference is considered to be part of this prospectus, and the information that we file later with the SEC will automatically update and supersede this information. We incorporate by reference into this prospectus the
        following documents:</div>
      <div style="text-align: justify; text-indent: 36pt;"> <br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000411/adma_10k.htm">March 25,
                        2021</a>;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">our definitive Proxy Statement on Schedule 14A for the 2021 Annual Meeting of Stockholders, filed <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000114036121012041/nc10021493x2_def14a.htm">April








                        7, 2021</a> (solely to the extent incorporated by reference into Part III of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020);</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000657/adma_10q.htm">May 12,
                        2021</a>;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">our Current Reports on Form 8-K filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000004/e620188_8k-adma.htm">January 4, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000045/e620209_8k-adma.htm">January 19, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000065/e620220_8k-adma.htm">January 26,
                        2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000106/e620239_8k-adma.htm">February 1, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000126/e620246_8k-adma.htm">February 3, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000299/e620325_8k-adma.htm">March 2,
                        2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000409/e620413_8k-adma.htm">March 25, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000549/e620523_8k-adma.htm">April








                        28, 2021</a>, <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000653/e620590_8k-adma.htm">May 12, 2021</a> and <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000749/e620651_8k-adma.htm">May 28, 2021</a> (provided that any portions of such reports that are deemed furnished and not filed pursuant to instructions to Form
                      8-K shall not be incorporated by reference into this prospectus); and</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div>
        <div>
          <div>
            <table class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;" cellpadding="0" cellspacing="0">

                <tr style="vertical-align: top;">
                  <td style="width: 36pt;">&#160;</td>
                  <td style="vertical-align: top; width: 18pt;">
                    <div style="text-align: left;"><font style="font-family: Times New Roman;">&#9679;</font></div>
                  </td>
                  <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left;">the description of common stock set forth in Exhibit 4.11 to our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/0001368514/000119380521000411/adma_ex411.htm">March 25, 2021</a>, including any amendment or report filed for the purpose of updating such description.</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">All documents subsequently filed with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering shall be deemed to be incorporated by reference
        into the prospectus. Any statement contained in any document incorporated by reference herein will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any additional
        prospectus supplements modifies or supersedes such statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.</div>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-19-</font></div>
        <div style="page-break-after:always;" id="DSPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" noshade="noshade"></div>
      </div>
      <!--PROfilePageNumberReset%Num%20%-%-%-->
      <div style="text-align: center; font-weight: bold;"><a name="LEGALMATTERS-2"><!--Anchor--></a>LEGAL MATTERS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The validity of the securities offered hereby will be passed upon for us by Morgan, Lewis &amp; Bockius LLP, Princeton, New Jersey. Any underwriters will be advised about other issues relating to
        any offering by their own legal counsel.</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;"><a name="EXPERTS-2"><!--Anchor--></a>EXPERTS</div>
      <div><br>
      </div>
      <div style="text-align: justify; text-indent: 36pt;">The consolidated financial statements incorporated in this prospectus by reference from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020 have been audited by
        CohnReznick LLP, an independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference, which report includes an explanatory paragraph on the Company&#8217;s ability to continue as
        a going concern. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</div>
      <div style="text-align: justify;"> <br>
      </div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageNumberArea" style="text-align: center;"><font id="DSPFPageNumber" style="font-size: 8pt; font-weight: normal; font-style: normal;">-20-</font></div>
        <div id="DSPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" noshade="noshade"></div>
      </div>
      <div style="text-align: center;"> <img src="ny20000594x1_424b5-image01.jpg"> </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;">
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-style: italic;">Up to $50,000,000</div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-style: italic;">Common Stock</div>
        <div><br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-style: italic;">PROSPECTUS</div>
        <div><br>
        </div>
        <table style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc120af5106554582905a68ee86e47dd4" cellpadding="0" cellspacing="0">

            <tr>
              <td style="width: 100%; vertical-align: top;">
                <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">Raymond James</div>
              </td>
            </tr>

        </table>
        <div>
          <div><br>
          </div>
          <div><br>
          </div>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The date of this prospectus is September 3, 2021</div>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
      <div style="text-align: justify;"> <br>
      </div>
    </div>
    <div style="text-align: center;">
      <hr style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;" align="center" noshade="noshade"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ny20000594x1_424b5-image01.jpg
<TEXT>
begin 644 ny20000594x1_424b5-image01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $-H:6UA;&$L
M(%)A9&AI:V$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,V
M.   DI(  @    ,V.   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MYJ$^2]Q*S\GH#T'X#BJ6/_K5]/0RRC&"]KJSY#$9M6E-^R=EZ(]<_P"%[_\
M4N_^3W_VNC_A>_\ U+G_ )/?_:Z\AI<5T?V;A?Y?Q?\ F<W]JXS^?\%_D>O?
M\+V_ZES_ ,GO_M='_"]O^I<_\GO_ +77D1&/\]*04?V=A-N3\7_F/^U,9OS_
M (+_ "/7?^%[_P#4N?\ D]_]KH_X7O\ ]2[_ .3W_P!KKR,8/ZTA%']FX7?E
M_%_YA_:N,_G_  7^1Z[_ ,+W_P"I<_\ )[_[72_\+W_ZEW_R>_\ M=>0Y%+A
M?\BC^SL+TC^+_P P_M3&?S_@O\CUW_A>_P#U+G_D]_\ :Z/^%[_]2Y_Y/?\
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MC_>3_&O,/%FJ:?K?B&;4M+M9;5+@!Y(Y<??[G@]ZI2Z/JL*EI],O(U'5F@8
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MDK-H:A63ND_N'_\ "8^)/^@Y??\ ?XU4O=<U34U"ZEJ-U=(O(668D9^E6/\
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M (FK4Z25DT2X5F[M/[B.S\1ZSIT"P:?JEW;PKTC28A1]!4Y\8>)#_P QV_\
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M.G=6_ I_6&K:_B9'^-:5EXCUK3H!!8ZK>00CI&DS!1UJ7_A$O$G_ $+^J?\
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1%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
